ID   DAB2P_HUMAN             Reviewed;        1189 AA.
AC   Q5VWQ8; A6H8V2; A6NHI9; B0QZB1; G3XA90; Q8TDL2; Q96SE1; Q9C0C0;
DT   17-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   18-JUN-2025, entry version 184.
DE   RecName: Full=Disabled homolog 2-interacting protein;
DE            Short=DAB2 interaction protein;
DE            Short=DAB2-interacting protein;
DE   AltName: Full=ASK-interacting protein 1;
DE            Short=AIP-1;
DE   AltName: Full=DOC-2/DAB-2 interactive protein;
GN   Name=DAB2IP {ECO:0000312|HGNC:HGNC:17294};
GN   Synonyms=AF9Q34, AIP1, KIAA1743;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND TISSUE SPECIFICITY.
RX   PubMed=11944990; DOI=10.1006/geno.2002.6739;
RA   Chen H., Pong R.-C., Wang Z., Hsieh J.-T.;
RT   "Differential regulation of the human gene DAB2IP in normal and malignant
RT   prostatic epithelia: cloning and characterization.";
RL   Genomics 79:573-581(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND CHROMOSOMAL TRANSLOCATION WITH
RP   KMT2A/MLL1.
RX   PubMed=14978793; DOI=10.1002/gcc.20004;
RA   von Bergh A.R.M., Wijers P.M., Groot A.J., van Zelderen-Bhola S.,
RA   Falkenburg J.H.F., Kluin P.M., Schuuring E.;
RT   "Identification of a novel RAS GTPase-activating protein (RASGAP) gene at
RT   9q34 as an MLL fusion partner in a patient with de novo acute myeloid
RT   leukemia.";
RL   Genes Chromosomes Cancer 39:324-334(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 7:347-355(2000).
RN   [4]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, INTERACTION WITH MAP3K5, AND MUTAGENESIS OF 228-LYS--LYS-230;
RP   281-LYS--LYS-284 AND ARG-413.
RX   PubMed=12813029; DOI=10.1172/jci17790;
RA   Zhang R., He X., Liu W., Lu M., Hsieh J.-T., Min W.;
RT   "AIP1 mediates TNF-alpha-induced ASK1 activation by facilitating
RT   dissociation of ASK1 from its inhibitor 14-3-3.";
RL   J. Clin. Invest. 111:1933-1943(2003).
RN   [9]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH TNFR1; MAP3K5; TRADD; RIPK1 AND
RP   TRAF2.
RX   PubMed=15310755; DOI=10.1074/jbc.m407617200;
RA   Zhang H., Zhang R., Luo Y., D'Alessio A., Pober J.S., Min W.;
RT   "AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-
RT   induced ASK1-JNK activation.";
RL   J. Biol. Chem. 279:44955-44965(2004).
RN   [10]
RP   INTERACTION WITH HIPK1, AND SUBCELLULAR LOCATION.
RX   PubMed=15701637; DOI=10.1074/jbc.m414262200;
RA   Li X., Zhang R., Luo D., Park S.-J., Wang Q., Kim Y., Min W.;
RT   "Tumor necrosis factor alpha-induced desumoylation and cytoplasmic
RT   translocation of homeodomain-interacting protein kinase 1 are critical for
RT   apoptosis signal-regulating kinase 1-JNK/p38 activation.";
RL   J. Biol. Chem. 280:15061-15070(2005).
RN   [11]
RP   FUNCTION, INTERACTION WITH 14-3-3 PROTEINS; MAP3K5; RIPK1 AND TRAF2,
RP   PHOSPHORYLATION AT SER-728, MUTAGENESIS OF SER-728 AND THR-935, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=17389591; DOI=10.1074/jbc.m701148200;
RA   Zhang H., Zhang H., Lin Y., Li J., Pober J.S., Min W.;
RT   "RIP1-mediated AIP1 phosphorylation at a 14-3-3-binding site is critical
RT   for tumor necrosis factor-induced ASK1-JNK/p38 activation.";
RL   J. Biol. Chem. 282:14788-14796(2007).
RN   [12]
RP   FUNCTION, AND MUTAGENESIS OF SER-728.
RX   PubMed=18292600; DOI=10.1161/circresaha.107.168153;
RA   Min W., Lin Y., Tang S., Yu L., Zhang H., Wan T., Luhn T., Fu H., Chen H.;
RT   "AIP1 recruits phosphatase PP2A to ASK1 in tumor necrosis factor-induced
RT   ASK1-JNK activation.";
RL   Circ. Res. 102:840-848(2008).
RN   [13]
RP   FUNCTION, INTERACTION WITH KDR AND P85 SUBUNIT OF PI3K, AND MUTAGENESIS OF
RP   228-LYS--LYS-230 AND 281-LYS--LYS-284.
RX   PubMed=19033661; DOI=10.1172/jci36168;
RA   Zhang H., He Y., Dai S., Xu Z., Luo Y., Wan T., Luo D., Jones D., Tang S.,
RA   Chen H., Sessa W.C., Min W.;
RT   "AIP1 functions as an endogenous inhibitor of VEGFR2-mediated signaling and
RT   inflammatory angiogenesis in mice.";
RL   J. Clin. Invest. 118:3904-3916(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   FUNCTION, INTERACTION WITH AKT1 AND P85 SUBUNIT OF PI3K, PHOSPHORYLATION AT
RP   SER-728, AND MUTAGENESIS OF ARG-413; SER-728 AND 920-PRO--PRO-929.
RX   PubMed=19903888; DOI=10.1073/pnas.0908458106;
RA   Xie D., Gore C., Zhou J., Pong R.C., Zhang H., Yu L., Vessella R.L.,
RA   Min W., Hsieh J.T.;
RT   "DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and
RT   apoptosis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:19878-19883(2009).
RN   [16]
RP   FUNCTION, INTERACTION WITH PHOSPHATIDYLINOSITOL, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF ARG-413.
RX   PubMed=19948740; DOI=10.1074/jbc.m109.069385;
RA   Wan T., Liu T., Zhang H., Tang S., Min W.;
RT   "AIP1 functions as Arf6-GAP to negatively regulate TLR4 signaling.";
RL   J. Biol. Chem. 285:3750-3757(2010).
RN   [17]
RP   FUNCTION IN PROSTATE CANCER, INDUCTION, AND MUTAGENESIS OF ARG-413 AND
RP   SER-728.
RX   PubMed=20154697; DOI=10.1038/nm.2100;
RA   Min J., Zaslavsky A., Fedele G., McLaughlin S.K., Reczek E.E., De Raedt T.,
RA   Guney I., Strochlic D.E., Macconaill L.E., Beroukhim R., Bronson R.T.,
RA   Ryeom S., Hahn W.C., Loda M., Cichowski K.;
RT   "An oncogene-tumor suppressor cascade drives metastatic prostate cancer by
RT   coordinately activating Ras and nuclear factor-kappaB.";
RL   Nat. Med. 16:286-294(2010).
RN   [18]
RP   FUNCTION IN PROSTATE CANCER, AND INTERACTION WITH GSK3B AND PPP2CA.
RX   PubMed=20080667; DOI=10.1073/pnas.0908133107;
RA   Xie D., Gore C., Liu J., Pong R.C., Mason R., Hao G., Long M., Kabbani W.,
RA   Yu L., Zhang H., Chen H., Sun X., Boothman D.A., Min W., Hsieh J.T.;
RT   "Role of DAB2IP in modulating epithelial-to-mesenchymal transition and
RT   prostate cancer metastasis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:2485-2490(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   FUNCTION, INTERACTION WITH JAK2, AND TISSUE SPECIFICITY.
RX   PubMed=21700930; DOI=10.1161/circresaha.111.248245;
RA   Yu L., Qin L., Zhang H., He Y., Chen H., Pober J.S., Tellides G., Min W.;
RT   "AIP1 prevents graft arteriosclerosis by inhibiting interferon-gamma-
RT   dependent smooth muscle cell proliferation and intimal expansion.";
RL   Circ. Res. 109:418-427(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-978, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [22]
RP   FUNCTION IN MEDULLOBLASTOMA DEVELOPMENT, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=22696229; DOI=10.1158/1078-0432.ccr-12-0399;
RA   Smits M., van Rijn S., Hulleman E., Biesmans D., van Vuurden D.G., Kool M.,
RA   Haberler C., Aronica E., Vandertop W.P., Noske D.P., Wurdinger T.;
RT   "EZH2-regulated DAB2IP is a medulloblastoma tumor suppressor and a positive
RT   marker for survival.";
RL   Clin. Cancer Res. 18:4048-4058(2012).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-747; SER-978 AND SER-995, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   FUNCTION, INTERACTION WITH RAB40C, MUTAGENESIS OF ARG-413, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=29156729; DOI=10.18632/oncotarget.19960;
RA   Luo X., Li C., Tan R., Xu X., Wu W.K.K., Satoh A., Wang T., Yu S.;
RT   "A RasGAP, DAB2IP, regulates lipid droplet homeostasis by serving as GAP
RT   toward RAB40C.";
RL   Oncotarget 8:85415-85427(2017).
CC   -!- FUNCTION: Functions as a scaffold protein implicated in the regulation
CC       of a large spectrum of both general and specialized signaling pathways.
CC       Involved in several processes such as innate immune response,
CC       inflammation and cell growth inhibition, apoptosis, cell survival,
CC       angiogenesis, cell migration and maturation. Also plays a role in cell
CC       cycle checkpoint control; reduces G1 phase cyclin levels resulting in
CC       G0/G1 cell cycle arrest. Mediates signal transduction by receptor-
CC       mediated inflammatory signals, such as the tumor necrosis factor (TNF),
CC       interferon (IFN) or lipopolysaccharide (LPS). Modulates the balance
CC       between phosphatidylinositol 3-kinase (PI3K)-AKT-mediated cell survival
CC       and apoptosis stimulated kinase (MAP3K5)-JNK signaling pathways;
CC       sequesters both AKT1 and MAP3K5 and counterbalances the activity of
CC       each kinase by modulating their phosphorylation status in response to
CC       pro-inflammatory stimuli. Acts as a regulator of the endoplasmic
CC       reticulum (ER) unfolded protein response (UPR) pathway; specifically
CC       involved in transduction of the ER stress-response to the JNK cascade
CC       through ERN1. Mediates TNF-alpha-induced apoptosis activation by
CC       facilitating dissociation of inhibitor 14-3-3 from MAP3K5; recruits the
CC       PP2A phosphatase complex which dephosphorylates MAP3K5 on 'Ser-966',
CC       leading to the dissociation of 13-3-3 proteins and activation of the
CC       MAP3K5-JNK signaling pathway in endothelial cells. Also mediates
CC       TNF/TRAF2-induced MAP3K5-JNK activation, while it inhibits CHUK-NF-
CC       kappa-B signaling. Acts a negative regulator in the IFN-gamma-mediated
CC       JAK-STAT signaling cascade by inhibiting smooth muscle cell (VSMCs)
CC       proliferation and intimal expansion, and thus, prevents graft
CC       arteriosclerosis (GA). Acts as a GTPase-activating protein (GAP) for
CC       the ADP ribosylation factor 6 (ARF6), Ras and RAB40C (PubMed:29156729).
CC       Promotes hydrolysis of the ARF6-bound GTP and thus, negatively
CC       regulates phosphatidylinositol 4,5-bisphosphate (PIP2)-dependent TLR4-
CC       TIRAP-MyD88 and NF-kappa-B signaling pathways in endothelial cells in
CC       response to lipopolysaccharides (LPS). Binds specifically to
CC       phosphatidylinositol 4-phosphate (PtdIns4P) and phosphatidylinositol 3-
CC       phosphate (PtdIns3P). In response to vascular endothelial growth factor
CC       (VEGFA), acts as a negative regulator of the VEGFR2-PI3K-mediated
CC       angiogenic signaling pathway by inhibiting endothelial cell migration
CC       and tube formation. In the developing brain, promotes both the
CC       transition from the multipolar to the bipolar stage and the radial
CC       migration of cortical neurons from the ventricular zone toward the
CC       superficial layer of the neocortex in a glial-dependent locomotion
CC       process. Probable downstream effector of the Reelin signaling pathway;
CC       promotes Purkinje cell (PC) dendrites development and formation of
CC       cerebellar synapses. Also functions as a tumor suppressor protein in
CC       prostate cancer progression; prevents cell proliferation and
CC       epithelial-to-mesenchymal transition (EMT) through activation of the
CC       glycogen synthase kinase-3 beta (GSK3B)-induced beta-catenin and
CC       inhibition of PI3K-AKT and Ras-MAPK survival downstream signaling
CC       cascades, respectively. {ECO:0000269|PubMed:12813029,
CC       ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:18292600,
CC       ECO:0000269|PubMed:19033661, ECO:0000269|PubMed:19903888,
CC       ECO:0000269|PubMed:19948740, ECO:0000269|PubMed:20080667,
CC       ECO:0000269|PubMed:20154697, ECO:0000269|PubMed:21700930,
CC       ECO:0000269|PubMed:22696229, ECO:0000269|PubMed:29156729}.
CC   -!- SUBUNIT: On plasma membrane, exists in an inactive form complexed with
CC       TNFR1; in response to TNF-alpha, dissociates from TNFR1 complex,
CC       translocates to cytoplasm and forms part of an intracellular signaling
CC       complex comprising TRADD, RIPK1, TRAF2 and MAP3K5. Interacts with DAB1.
CC       Interacts (via NPXY motif) with DAB2 (via PID domain). Interacts (via
CC       PH domain) with ERN1 (By similarity). Part of a cytoplasmic complex
CC       made of HIPK1, DAB2IP and MAP3K5 in response to TNF-alpha; this complex
CC       formation promotes MAP3K5-JNK activation and subsequent apoptosis.
CC       Interacts (via N-terminal domain) with JAK2; the interaction occurs in
CC       a IFNG/IFN-gamma-dependent manner and inhibits JAK2 autophosphorylation
CC       activity. Interacts (via C2 domain) with GSK3B; the interaction
CC       stimulates GSK3B kinase activation. Interacts (via C2 domain) with
CC       PPP2CA. Interacts (via proline-rich motif) with a regulatory p85
CC       subunit (via SH3 domain) of the PI3K complex; the interaction inhibits
CC       the PI3K-AKT complex activity in a TNF-alpha-dependent manner in
CC       prostate cancer (PCa) cells. Interacts with AKT1; the interaction is
CC       increased in a TNF-alpha-induced manner. Interacts (via C2 domain and
CC       active form preferentially) with KDR/VEGFR2 (tyrosine-phosphorylated
CC       active form preferentially); the interaction occurs at the late phase
CC       of VEGFA response and inhibits KDR/VEGFR2 activity. Interacts (via N-
CC       terminus C2 domain) with MAP3K5 ('Ser-966' dephosphorylated form
CC       preferentially); the interaction occurs in a TNF-alpha-induced manner.
CC       Interacts (via Ras-GAP domain) with the catalytic subunit of protein
CC       phosphatase PP2A; the interaction occurs in resting endothelial cells,
CC       is further enhanced by TNF-alpha stimulation and is required to bridge
CC       PP2A to MAP3K5. Interacts (via C-terminus PER domain) with TRAF2 (via
CC       zinc fingers); the interaction occurs in a TNF-alpha-dependent manner.
CC       Interacts with 14-3-3 proteins; the interaction occurs in a TNF-alpha-
CC       dependent manner. Interacts (via Ras-GAP domain) with RIPK1 (via kinase
CC       domain); the interaction occurs in a TNF-alpha-dependent manner.
CC       Interacts with RAB40C; acts as a GAP for RAB40C (PubMed:29156729).
CC       {ECO:0000250, ECO:0000269|PubMed:12813029, ECO:0000269|PubMed:15310755,
CC       ECO:0000269|PubMed:15701637, ECO:0000269|PubMed:17389591,
CC       ECO:0000269|PubMed:19033661, ECO:0000269|PubMed:19903888,
CC       ECO:0000269|PubMed:19948740, ECO:0000269|PubMed:20080667,
CC       ECO:0000269|PubMed:21700930, ECO:0000269|PubMed:29156729}.
CC   -!- INTERACTION:
CC       Q5VWQ8; Q5VWQ8: DAB2IP; NbExp=2; IntAct=EBI-2871881, EBI-2871881;
CC       Q5VWQ8; P49841: GSK3B; NbExp=2; IntAct=EBI-2871881, EBI-373586;
CC       Q5VWQ8; Q99683: MAP3K5; NbExp=2; IntAct=EBI-2871881, EBI-476263;
CC       Q5VWQ8-2; O15169: AXIN1; NbExp=2; IntAct=EBI-9543020, EBI-710484;
CC       Q5VWQ8-2; P49841: GSK3B; NbExp=2; IntAct=EBI-9543020, EBI-373586;
CC       Q5VWQ8-5; Q49AR9: ANKS1A; NbExp=3; IntAct=EBI-12196395, EBI-11954519;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:29156729}. Cell
CC       membrane {ECO:0000269|PubMed:29156729}; Peripheral membrane protein
CC       {ECO:0000305}. Membrane {ECO:0000269|PubMed:29156729}. Cell projection,
CC       dendrite {ECO:0000250}. Note=Localized in soma and dendrites of
CC       Purkinje cells as well as in scattered cell bodies in the molecular
CC       layer of the cerebellum (By similarity). Colocalizes with TIRAP at the
CC       plasma membrane. Colocalizes with ARF6 at the plasma membrane and
CC       endocytic vesicles. Translocates from the plasma membrane to the
CC       cytoplasm in response to TNF-alpha. Phosphatidylinositol 4-phosphate
CC       (PtdIns4P) binding is essential for plasma membrane localization.
CC       Localized in the cytoplasmic space in close proximity to lipid droplets
CC       (PubMed:29156729). {ECO:0000250, ECO:0000269|PubMed:29156729}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q5VWQ8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q5VWQ8-2; Sequence=VSP_020953;
CC       Name=3;
CC         IsoId=Q5VWQ8-3; Sequence=VSP_020952, VSP_020954;
CC       Name=4;
CC         IsoId=Q5VWQ8-4; Sequence=VSP_020953, VSP_020954;
CC       Name=5;
CC         IsoId=Q5VWQ8-5; Sequence=VSP_047361, VSP_020954;
CC   -!- TISSUE SPECIFICITY: Expressed in endothelial and vascular smooth muscle
CC       cells (VSMCs). Expressed in prostate epithelial but poorly in prostate
CC       cancer cells. Poorly expressed in medulloblastoma cells compared to
CC       cerebellar precursor proliferating progenitor cells (at protein level).
CC       Low expression in prostate. Down-regulated in prostate cancer.
CC       {ECO:0000269|PubMed:11944990, ECO:0000269|PubMed:17389591,
CC       ECO:0000269|PubMed:21700930, ECO:0000269|PubMed:22696229}.
CC   -!- INDUCTION: Down-regulated in prostate cancer and medulloblastoma.
CC       {ECO:0000269|PubMed:20154697, ECO:0000269|PubMed:22696229}.
CC   -!- DOMAIN: The C2 and Ras-GAP domains constitutively bind to MAP3K5 and
CC       facilitate the release of 14-3-3 proteins from MAP3K5. The PH and Ras-
CC       GAP domains, but not the NPXY motif, are crucial for its cell membrane
CC       localization and neuronal migration function. The PH domain is
CC       necessary but not sufficient to activate the JNK signaling pathway
CC       through ERN1 (By similarity). Exists in a closed inactive form by an
CC       intramolecular interaction between the N- and the C-terminal domains.
CC       The proline-rich motif is critical both for PI3K-AKT activity
CC       inhibition and MAP3K5 activation. The PH and C2 domains are necessary
CC       for the binding to phosphatidylinositol phosphate. The Ras-GAP domain
CC       is necessary for its tumor-suppressive function. {ECO:0000250}.
CC   -!- PTM: In response to TNF-alpha-induction, phosphorylated at Ser-728;
CC       phosphorylation leads to a conformational change, and thus, increases
CC       its association with 14-3-3 proteins, MAP3K5, RIPK1 and TRAF2 in
CC       endothelial cells; also stimulates regulatory p85 subunit sequestring
CC       and PI3K-p85 complex activity inhibition. {ECO:0000269|PubMed:17389591,
CC       ECO:0000269|PubMed:19903888}.
CC   -!- DISEASE: Note=A chromosomal aberration involving DAB2IP is found in a
CC       patient with acute myeloid leukemia (AML). Translocation
CC       t(9;11)(q34;q23) with KMT2A/MLL1. May give rise to a KMT2A/MLL1-DAB2IP
CC       fusion protein lacking the PH domain (PubMed:14978793).
CC       {ECO:0000269|PubMed:14978793}.
CC   -!- MISCELLANEOUS: The DAB2IP gene is found epigenetically silenced in
CC       numerous aggressive cancers, like prostate cancers and medulloblastoma
CC       tumors. Epigenetic suppression of DAB2IP by EZH2 is a major mechanism
CC       of DAB2IP inactivation in human prostate cancer and increases
CC       metastatic potential (PubMed:20154697, PubMed:22696229).
CC       {ECO:0000305|PubMed:20154697, ECO:0000305|PubMed:22696229}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/316/AF9q34";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF367051; AAM00371.1; -; mRNA.
DR   EMBL; AY032952; AAK50336.1; -; mRNA.
DR   EMBL; AB051530; BAB21834.2; -; mRNA.
DR   EMBL; AL357936; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL365274; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471090; EAW87503.1; -; Genomic_DNA.
DR   EMBL; CH471090; EAW87504.1; -; Genomic_DNA.
DR   EMBL; BC146762; AAI46763.1; -; mRNA.
DR   CCDS; CCDS6832.1; -. [Q5VWQ8-2]
DR   CCDS; CCDS6833.2; -. [Q5VWQ8-5]
DR   CCDS; CCDS94477.1; -. [Q5VWQ8-1]
DR   RefSeq; NP_001381939.1; NM_001395010.1. [Q5VWQ8-1]
DR   RefSeq; NP_115941.2; NM_032552.4. [Q5VWQ8-5]
DR   RefSeq; NP_619723.1; NM_138709.2. [Q5VWQ8-2]
DR   RefSeq; XP_005251776.1; XM_005251719.4.
DR   RefSeq; XP_011516572.1; XM_011518270.2.
DR   RefSeq; XP_011516573.1; XM_011518271.2.
DR   RefSeq; XP_016869789.1; XM_017014300.1.
DR   AlphaFoldDB; Q5VWQ8; -.
DR   SMR; Q5VWQ8; -.
DR   BioGRID; 127478; 82.
DR   DIP; DIP-41721N; -.
DR   FunCoup; Q5VWQ8; 835.
DR   IntAct; Q5VWQ8; 43.
DR   MINT; Q5VWQ8; -.
DR   STRING; 9606.ENSP00000259371; -.
DR   ChEMBL; CHEMBL4523330; -.
DR   CarbonylDB; Q5VWQ8; -.
DR   GlyGen; Q5VWQ8; 1 site.
DR   iPTMnet; Q5VWQ8; -.
DR   PhosphoSitePlus; Q5VWQ8; -.
DR   BioMuta; DAB2IP; -.
DR   DMDM; 116247768; -.
DR   jPOST; Q5VWQ8; -.
DR   MassIVE; Q5VWQ8; -.
DR   PaxDb; 9606-ENSP00000259371; -.
DR   PeptideAtlas; Q5VWQ8; -.
DR   ProteomicsDB; 33682; -.
DR   ProteomicsDB; 65554; -. [Q5VWQ8-1]
DR   ProteomicsDB; 65555; -. [Q5VWQ8-2]
DR   ProteomicsDB; 65556; -. [Q5VWQ8-3]
DR   ProteomicsDB; 65557; -. [Q5VWQ8-4]
DR   Pumba; Q5VWQ8; -.
DR   Antibodypedia; 48362; 112 antibodies from 20 providers.
DR   DNASU; 153090; -.
DR   Ensembl; ENST00000259371.7; ENSP00000259371.2; ENSG00000136848.19. [Q5VWQ8-5]
DR   Ensembl; ENST00000309989.1; ENSP00000310827.1; ENSG00000136848.19. [Q5VWQ8-2]
DR   Ensembl; ENST00000408936.8; ENSP00000386183.3; ENSG00000136848.19. [Q5VWQ8-1]
DR   GeneID; 153090; -.
DR   KEGG; hsa:153090; -.
DR   MANE-Select; ENST00000408936.8; ENSP00000386183.3; NM_001395010.1; NP_001381939.1.
DR   UCSC; uc004bln.5; human. [Q5VWQ8-1]
DR   AGR; HGNC:17294; -.
DR   CTD; 153090; -.
DR   DisGeNET; 153090; -.
DR   GeneCards; DAB2IP; -.
DR   HGNC; HGNC:17294; DAB2IP.
DR   HPA; ENSG00000136848; Low tissue specificity.
DR   MIM; 609205; gene.
DR   neXtProt; NX_Q5VWQ8; -.
DR   OpenTargets; ENSG00000136848; -.
DR   PharmGKB; PA27133; -.
DR   VEuPathDB; HostDB:ENSG00000136848; -.
DR   eggNOG; KOG3508; Eukaryota.
DR   GeneTree; ENSGT00940000155853; -.
DR   HOGENOM; CLU_001727_1_0_1; -.
DR   InParanoid; Q5VWQ8; -.
DR   OMA; PWKPDLV; -.
DR   OrthoDB; 5572587at2759; -.
DR   PAN-GO; Q5VWQ8; 0 GO annotations based on evolutionary models.
DR   PhylomeDB; Q5VWQ8; -.
DR   TreeFam; TF105303; -.
DR   PathwayCommons; Q5VWQ8; -.
DR   Reactome; R-HSA-5658442; Regulation of RAS by GAPs.
DR   SignaLink; Q5VWQ8; -.
DR   SIGNOR; Q5VWQ8; -.
DR   BioGRID-ORCS; 153090; 19 hits in 1148 CRISPR screens.
DR   CD-CODE; FB4E32DD; Presynaptic clusters and postsynaptic densities.
DR   ChiTaRS; DAB2IP; human.
DR   GeneWiki; DAB2IP; -.
DR   GenomeRNAi; 153090; -.
DR   Pharos; Q5VWQ8; Tchem.
DR   PRO; PR:Q5VWQ8; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q5VWQ8; protein.
DR   Bgee; ENSG00000136848; Expressed in right hemisphere of cerebellum and 179 other cell types or tissues.
DR   ExpressionAtlas; Q5VWQ8; baseline and differential.
DR   GO; GO:1990597; C:AIP1-IRE1 complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0044300; C:cerebellar mossy fiber; ISS:UniProtKB.
DR   GO; GO:0044301; C:climbing fiber; ISS:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; ISS:UniProtKB.
DR   GO; GO:0032809; C:neuronal cell body membrane; ISS:UniProtKB.
DR   GO; GO:1990032; C:parallel fiber; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0071889; F:14-3-3 protein binding; IDA:BHF-UCL.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0005123; F:death receptor binding; IPI:BHF-UCL.
DR   GO; GO:0005096; F:GTPase activator activity; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019900; F:kinase binding; IPI:UniProtKB.
DR   GO; GO:0031434; F:mitogen-activated protein kinase kinase binding; IPI:UniProtKB.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IPI:BHF-UCL.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IDA:UniProtKB.
DR   GO; GO:0036312; F:phosphatidylinositol 3-kinase regulatory subunit binding; IDA:UniProtKB.
DR   GO; GO:0032266; F:phosphatidylinositol-3-phosphate binding; IDA:UniProtKB.
DR   GO; GO:0070273; F:phosphatidylinositol-4-phosphate binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051721; F:protein phosphatase 2A binding; IPI:BHF-UCL.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IDA:GO_Central.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IDA:UniProtKB.
DR   GO; GO:0035591; F:signaling adaptor activity; IDA:GO_Central.
DR   GO; GO:0043184; F:vascular endothelial growth factor receptor 2 binding; IPI:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0021814; P:cell motility involved in cerebral cortex radial glia guided migration; ISS:UniProtKB.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; ISS:BHF-UCL.
DR   GO; GO:0071347; P:cellular response to interleukin-1; IDA:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0034620; P:cellular response to unfolded protein; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0035924; P:cellular response to vascular endothelial growth factor stimulus; IDA:UniProtKB.
DR   GO; GO:0072577; P:endothelial cell apoptotic process; TAS:BHF-UCL.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; IMP:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0035556; P:intracellular signal transduction; IMP:UniProtKB.
DR   GO; GO:0070059; P:intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress; ISS:BHF-UCL.
DR   GO; GO:0021819; P:layer formation in cerebral cortex; ISS:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:UniProtKB.
DR   GO; GO:0043124; P:negative regulation of canonical NF-kappaB signal transduction; IDA:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0010633; P:negative regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0010719; P:negative regulation of epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0070373; P:negative regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; ISS:BHF-UCL.
DR   GO; GO:0070317; P:negative regulation of G0 to G1 transition; IDA:UniProtKB.
DR   GO; GO:0034260; P:negative regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:0043409; P:negative regulation of MAPK cascade; IMP:BHF-UCL.
DR   GO; GO:1901223; P:negative regulation of non-canonical NF-kappaB signal transduction; IMP:BHF-UCL.
DR   GO; GO:0051898; P:negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; IDA:UniProtKB.
DR   GO; GO:0042177; P:negative regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0046580; P:negative regulation of Ras protein signal transduction; IMP:BHF-UCL.
DR   GO; GO:0034144; P:negative regulation of toll-like receptor 4 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0030948; P:negative regulation of vascular endothelial growth factor receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:1900747; P:negative regulation of vascular endothelial growth factor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048812; P:neuron projection morphogenesis; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of canonical NF-kappaB signal transduction; ISS:UniProtKB.
DR   GO; GO:1900006; P:positive regulation of dendrite development; ISS:UniProtKB.
DR   GO; GO:1903896; P:positive regulation of IRE1-mediated unfolded protein response; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:UniProtKB.
DR   GO; GO:2001224; P:positive regulation of neuron migration; ISS:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:1901800; P:positive regulation of proteasomal protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; ISS:UniProtKB.
DR   GO; GO:0031334; P:positive regulation of protein-containing complex assembly; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0090129; P:positive regulation of synapse maturation; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0030163; P:protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0043122; P:regulation of canonical NF-kappaB signal transduction; ISS:UniProtKB.
DR   GO; GO:0051726; P:regulation of cell cycle; IDA:UniProtKB.
DR   GO; GO:0043087; P:regulation of GTPase activity; ISS:UniProtKB.
DR   GO; GO:1900744; P:regulation of p38MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0043254; P:regulation of protein-containing complex assembly; IDA:UniProtKB.
DR   GO; GO:0035148; P:tube formation; IMP:UniProtKB.
DR   GO; GO:0033209; P:tumor necrosis factor-mediated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0036324; P:vascular endothelial growth factor receptor-2 signaling pathway; ISS:UniProtKB.
DR   CDD; cd04013; C2_SynGAP_like; 1.
DR   CDD; cd13376; PH_DAB2IP; 1.
DR   CDD; cd05136; RasGAP_DAB2IP; 1.
DR   FunFam; 1.10.506.10:FF:000001; Ras GTPase-activating protein nGAP isoform 2; 1.
DR   FunFam; 2.60.40.150:FF:000010; Ras GTPase-activating protein nGAP isoform 2; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 1.10.506.10; GTPase Activation - p120gap, domain 1; 2.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR021887; DAB2P_C.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR039360; Ras_GTPase.
DR   InterPro; IPR023152; RasGAP_CS.
DR   InterPro; IPR001936; RasGAP_dom.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   PANTHER; PTHR10194:SF26; DISABLED HOMOLOG 2-INTERACTING PROTEIN; 1.
DR   PANTHER; PTHR10194; RAS GTPASE-ACTIVATING PROTEINS; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF12004; DAB2P_C; 1.
DR   Pfam; PF25321; PH_RASGAP; 1.
DR   Pfam; PF00616; RasGAP; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00323; RasGAP; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF48350; GTPase activation domain, GAP; 1.
DR   SUPFAM; SSF50729; PH domain-like; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00509; RAS_GTPASE_ACTIV_1; 1.
DR   PROSITE; PS50018; RAS_GTPASE_ACTIV_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Angiogenesis; Apoptosis; Cell cycle; Cell membrane;
KW   Cell projection; Chromosomal rearrangement; Coiled coil; Cytoplasm;
KW   Developmental protein; Growth regulation; GTPase activation; Immunity;
KW   Inflammatory response; Innate immunity; Membrane; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Stress response;
KW   Tumor suppressor; Unfolded protein response.
FT   CHAIN           1..1189
FT                   /note="Disabled homolog 2-interacting protein"
FT                   /id="PRO_0000252407"
FT   DOMAIN          101..202
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          193..311
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          387..595
FT                   /note="Ras-GAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00167"
FT   REGION          1..75
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          646..943
FT                   /note="Necessary for interaction with AKT1"
FT                   /evidence="ECO:0000269|PubMed:19903888"
FT   REGION          653..678
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          715..742
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          803..823
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          843..865
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          895..998
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1015..1035
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1164..1189
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          1026..1159
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        20..38
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        39..49
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        653..668
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        669..678
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        715..731
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        852..865
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        919..931
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        938..955
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        966..976
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1023..1035
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            172..173
FT                   /note="Breakpoint for translocation to form KMT2A/MLL1-
FT                   DAB2IP"
FT   SITE            413
FT                   /note="Arginine finger; crucial for GTP hydrolysis by
FT                   stabilizing the transition state"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00167"
FT   MOD_RES         728
FT                   /note="Phosphoserine; by MAP3K5 and RIPK1"
FT                   /evidence="ECO:0000269|PubMed:17389591,
FT                   ECO:0000269|PubMed:19903888"
FT   MOD_RES         747
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         978
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         995
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..193
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11944990"
FT                   /id="VSP_020952"
FT   VAR_SEQ         1..124
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:11214970,
FT                   ECO:0000303|PubMed:14978793, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_020953"
FT   VAR_SEQ         2..41
FT                   /note="SAGGSARKSTGRSSYYYRLLRRPRLQRQRSRSRSRTRPAR -> EPDSLLDQ
FT                   DDSY (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_047361"
FT   VAR_SEQ         1158..1189
FT                   /note="RYSMQARNGISPTNPTKLQITENGEFRNSSNC -> SMH (in isoform
FT                   3, isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:11214970,
FT                   ECO:0000303|PubMed:11944990, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_020954"
FT   VARIANT         59
FT                   /note="S -> F (in dbSNP:rs7027492)"
FT                   /id="VAR_056858"
FT   MUTAGEN         228..230
FT                   /note="KKK->AAA: Reduces interaction with KDR/VEGFR2. Does
FT                   not inhibit interaction with MAP3K5."
FT                   /evidence="ECO:0000269|PubMed:12813029,
FT                   ECO:0000269|PubMed:19033661"
FT   MUTAGEN         281..284
FT                   /note="KKKK->AAAA: Significantly reduces interaction with
FT                   MAP3K5. Does not reduce interaction with KDR/VEGFR2."
FT                   /evidence="ECO:0000269|PubMed:12813029,
FT                   ECO:0000269|PubMed:19033661"
FT   MUTAGEN         413
FT                   /note="R->L: Decreased GAP activity toward RAB40C. Does not
FT                   inhibit interaction with MAP3K5. Does not reduce
FT                   GSK3B-induced beta-catenin transcription activity,
FT                   TNF-alpha-induced apoptosis, ARF6-mediated TLR4-TIRAP-MyD88
FT                   signaling inhibition, Ras and NF-kappa-B activities and
FT                   tumor development. Does not suppress tumor development;
FT                   when associated with A-728."
FT                   /evidence="ECO:0000269|PubMed:12813029,
FT                   ECO:0000269|PubMed:19903888, ECO:0000269|PubMed:19948740,
FT                   ECO:0000269|PubMed:20154697, ECO:0000269|PubMed:29156729"
FT   MUTAGEN         728
FT                   /note="S->A: Inhibits phosphorylation and TNF-alpha-induced
FT                   MAP3K5 dephosphorylation. Reduces interaction with 14-3-3
FT                   proteins, AKT1, a regulatory p85 subunit, MAP3K5, RIPK1,
FT                   TRAF2 and TNF-alpha-induced MAP3K5-JNK signaling and
FT                   apoptosis. Reduces RAS activity. Does not reduce
FT                   GSK3B-induced beta catenin-mediated transcription activity.
FT                   Does not reduce NF-kappa-B activity, cell invasion,
FT                   epithelial-to-mesenchymal transition (EMT) and tumor
FT                   development. Does not suppress tumor development; when
FT                   associated with R-413."
FT                   /evidence="ECO:0000269|PubMed:17389591,
FT                   ECO:0000269|PubMed:18292600, ECO:0000269|PubMed:19903888,
FT                   ECO:0000269|PubMed:20154697"
FT   MUTAGEN         920..929
FT                   /note="PPPPPPPPPP->AAAAAAAAAA: Reduces interaction with a
FT                   regulatory p85 subunit of the PI3K complex. Inhibits MAP3K5
FT                   active form increase, AKT1 active form decrease, PI3K-p85
FT                   complex activity inhibition and TNF-induced apoptosis."
FT                   /evidence="ECO:0000269|PubMed:19903888"
FT   MUTAGEN         935
FT                   /note="T->A: Does not reduce interaction with 14-3-3
FT                   proteins."
FT                   /evidence="ECO:0000269|PubMed:17389591"
FT   CONFLICT        482
FT                   /note="I -> T (in Ref. 1; AAM00371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        921
FT                   /note="P -> S (in Ref. 1; AAM00371)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1091..1092
FT                   /note="QQ -> HE (in Ref. 1; AAM00371)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1189 AA;  131625 MW;  7494FF05AACF3320 CRC64;
     MSAGGSARKS TGRSSYYYRL LRRPRLQRQR SRSRSRTRPA RESPQERPGS RRSLPGSLSE
     KSPSMEPSAA TPFRVTGFLS RRLKGSIKRT KSQPKLDRNH SFRHILPGFR SAAAAAADNE
     RSHLMPRLKE SRSHESLLSP SSAVEALDLS MEEEVVIKPV HSSILGQDYC FEVTTSSGSK
     CFSCRSAAER DKWMENLRRA VHPNKDNSRR VEHILKLWVI EAKDLPAKKK YLCELCLDDV
     LYARTTGKLK TDNVFWGEHF EFHNLPPLRT VTVHLYRETD KKKKKERNSY LGLVSLPAAS
     VAGRQFVEKW YPVVTPNPKG GKGPGPMIRI KARYQTITIL PMEMYKEFAE HITNHYLGLC
     AALEPILSAK TKEEMASALV HILQSTGKVK DFLTDLMMSE VDRCGDNEHL IFRENTLATK
     AIEEYLKLVG QKYLQDALGE FIKALYESDE NCEVDPSKCS AADLPEHQGN LKMCCELAFC
     KIINSYCVFP RELKEVFASW RQECSSRGRP DISERLISAS LFLRFLCPAI MSPSLFNLLQ
     EYPDDRTART LTLIAKVTQN LANFAKFGSK EEYMSFMNQF LEHEWTNMQR FLLEISNPET
     LSNTAGFEGY IDLGRELSSL HSLLWEAVSQ LEQSIVSKLG PLPRILRDVH TALSTPGSGQ
     LPGTNDLAST PGSGSSSISA GLQKMVIEND LSGLIDFTRL PSPTPENKDL FFVTRSSGVQ
     PSPARSSSYS EANEPDLQMA NGGKSLSMVD LQDARTLDGE AGSPAGPDVL PTDGQAAAAQ
     LVAGWPARAT PVNLAGLATV RRAGQTPTTP GTSEGAPGRP QLLAPLSFQN PVYQMAAGLP
     LSPRGLGDSG SEGHSSLSSH SNSEELAAAA KLGSFSTAAE ELARRPGELA RRQMSLTEKG
     GQPTVPRQNS AGPQRRIDQP PPPPPPPPPA PRGRTPPNLL STLQYPRPSS GTLASASPDW
     VGPSTRLRQQ SSSSKGDSPE LKPRAVHKQG PSPVSPNALD RTAAWLLTMN AQLLEDEGLG
     PDPPHRDRLR SKDELSQAEK DLAVLQDKLR ISTKKLEEYE TLFKCQEETT QKLVLEYQAR
     LEEGEERLRR QQEDKDIQMK GIISRLMSVE EELKKDHAEM QAAVDSKQKI IDAQEKRIAS
     LDAANARLMS ALTQLKERYS MQARNGISPT NPTKLQITEN GEFRNSSNC
//
